涉嫌单位行贿罪，信邦制药被公诉

Core Viewpoint - Xinfeng Pharmaceutical (002390.SZ) is facing legal challenges as it has been indicted for alleged corporate bribery, which may negatively impact its profits. The company is actively working to mitigate potential risks and has engaged legal counsel to defend its interests [1][6]. Group 1: Legal Issues - The company received an indictment from the People's Procuratorate of Kaiyang County, Guizhou, for alleged corporate bribery [1][6]. - The case is currently in the court's review stage, and the company has not yet appeared in court [1][6]. - Xinfeng Pharmaceutical holds a 99.9964% stake in its subsidiary, Guizhou Kekai Pharmaceutical Co., Ltd., which is also implicated in the bribery case [1][6]. Group 2: Financial Impact - The company anticipates that the legal issues may have a negative impact on its profits, although it cannot accurately assess the specific effects at this time [2][7]. - In 2023, Guizhou Kekai Pharmaceutical reported revenues of 2.278 billion yuan, net profits of 94.5025 million yuan, and net assets of 2.482 billion yuan, contributing 35.26%, 26.71%, and 34.75% to Xinfeng Pharmaceutical's respective financial metrics [1][6]. Group 3: Company Performance - Xinfeng Pharmaceutical's performance has been declining, with a reported revenue of 4.266 billion yuan for the first three quarters of 2025, a year-on-year decrease of 6.55% [10]. - The net profit attributable to shareholders for the same period was 152 million yuan, down 13.74% year-on-year [10]. - The company's total assets at the end of the reporting period were 8.592 billion yuan, with accounts receivable amounting to 2.441 billion yuan [10].